Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HRH2 | P25021 | 15/20 | 0.54 |
| ▸ | HRH1 | P35367 | 15/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991910 | 0.92 | HRH2 (0.56) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL4050766 | 0.85 | ALDH1A1 (0.53) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL9405372 | 0.85 | POLB (0.73) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL46979 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL30404652 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL27166403 | 0.83 | HRH2 (0.56) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL4199473 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL5594524 | 0.82 | POLB (0.65) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL5724486 | 0.81 | TSHR (0.43) | SMN1; SMN2LMNAPOLBHRH2HRH1 | |
| SCHEMBL523279 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAPOLBHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2025-12-23 | — | — | US | disclosed |
| WO-2024112122-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024105007-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-01-12 | — | — | US | disclosed |
| EP-1989200-B1 | [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-0977751-A4 | SOMATOSTATIN AGONISTS | MERCK & CO INC (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6025372-A | Somatostatin agonists | MERCK & CO., INC. (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0977751-A1 | SOMATOSTATIN AGONISTS | Merck & Co., Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998045285-A1 | SOMATOSTATIN AGONISTS | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | EZH2, BMI1, SUZ12 | SMN1; SMN2 2636/4885LMNA 2051/4885POLB 2422/4885 |
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | EZH2, BMI1, SUZ12 | SMN1; SMN2 2636/4885LMNA 2051/4885POLB 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.